Skip to content

A clinical study to evaluate the effectiveness of kasisa bhasma in the management of urinary stones (urolithiasis)

A Randomised Controlled Trial to Evaluate the Efficacy of Kasisa Bhasma in the Management of Mutrashmari W.S.R. to Urolithiasis. - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/03/106263
Enrollment
60
Registered
2026-03-16
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N22- Calculus of urinary tract in diseases classified elsewhere

Interventions

None listed

Sponsors

Dr Bhupesh sahu
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients aged between 20-60 years 2.Patients with clinical features of urolithiasis like pain abdomen, pain in bladder region, burning micturition, hematuria, obstruction in urine flow 3.Size of calculi less than 10mm 4.Number of calculi less than or equal to 4.

Exclusion criteria

Exclusion criteria: 1.size of calculi more than 10mm or requiring immediate surgical intervention. 2.Patients with severe renal impairment, moderate to severe hydronephrosis, staghorn calculus, impacted calculi or stones present in the lower pole of the kidney 3.Patients with uncontrolled Diabetes Mellitus and severe Hypertension 4.Pregnant and Lactating women

Design outcomes

Primary

MeasureTime frame
1. Size of the calculi 2. Descent of the calculiTimepoint: Before treatment and 30th Day

Secondary

MeasureTime frame
Reduce in 1. Pain in the abdomen, flank pain 2. Hematuria 3. Dysuria 4. Burning micturitionTimepoint: Before treatment and 30th Day

Countries

India

Contacts

Public ContactDr Pawan B Lalsange

Dr N.A. Magadum Ayurvedic Medical College Hospital and Research centre Ankali

ambiciouspawan@gmail.com8748035055

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026